Juvenile Idiopathic Arthritis Assessment and Management Strategies

Juvenile idiopathic arthritis (JIA) represents a spectrum of chronic paediatric rheumatic diseases marked by persistent joint inflammation of unknown aetiology. Classification is based on the number of joints affected, systemic features and serological markers, yielding oligoarticular, polyarticular, systemic, psoriatic and enthesitis-related subtypes. Assessment combines clinical evaluation with standardised composite indices, most notably the Juvenile Disease Activity Score (JADAS), alongside imaging techniques such as ultrasound and magnetic resonance to detect subclinical synovitis. Patient-reported outcome measures have gained prominence to capture pain, function and quality of life. Management has evolved towards a treat-to-target paradigm in which tight control of inflammation and regular reassessment guide therapeutic escalation. Conventional synthetic DMARDs, chiefly methotrexate, remain first line for peripheral disease, often supplemented by intra-articular corticosteroids. The advent of biologic agents targeting tumour necrosis factor, interleukin-1 and interleukin-6 has transformed outcomes, particularly in refractory or systemic cases. A multidisciplinary team including paediatric rheumatologists, ophthalmologists, physiotherapists and psychologists is essential to address musculoskeletal health, prevent complications such as uveitis, support growth and optimise psychosocial development. Emerging biomarker research and digital health tools aim to refine individual risk stratification, predict response to therapy and enhance self-management.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Juvenile Idiopathic Arthritis Assessment and Management Strategies publication trend

The graph below shows the total number of articles in juvenile idiopathic arthritis assessment and management strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Juvenile Disease Activity Score (JADAS): A validated composite index combining physician assessment, joint count, acute-phase reactants and patient/parent global evaluation to quantify disease activity.

Disease-modifying anti-rheumatic drugs (DMARDs): Medications that slow or halt the underlying inflammatory process in arthritis, beyond mere symptom relief.

Biologic agent: A protein-based therapeutic, typically a monoclonal antibody or receptor fusion, designed to inhibit specific immune mediators such as cytokines or cell-surface molecules.

Treat-to-target: A therapeutic strategy involving predefined goals (remission or low disease activity) and frequent adjustments to therapy to achieve optimal control.

Uveitis: Intraocular inflammation of the uveal tract, a potentially sight-threatening complication in certain JIA subtypes.

References

1. Clinical outcome measures in juvenile idiopathic arthritis. Pediatric Rheumatology (2016).
2. Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches. Pediatric Rheumatology (2021).
3. Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting. Pediatric Rheumatology (2018).
4. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries. Arthritis Research & Therapy (2018).
5. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry. Arthritis Research & Therapy (2017).
6. MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis. Arthritis Research & Therapy (2015).
7. Developing and Evaluating JIApp: Acceptability and Usability of a Smartphone App System to Improve Self-Management in Young People With Juvenile Idiopathic Arthritis. JMIR mHealth and uHealth (2017).